Handbook of Chronic Myeloid Leukemia

This concise, clinically focused pocket handbook assembles and synthesizes the latest developments and trends in the diagnosis and treatment of CML and provides an authoritative and convenient summary of the latest progress in TKI trials, the molecular monitoring of CML responses, and the developmen...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autores principales: Hughes, Timothy P. (Autor), Ross, David M. (Autor), Melo, Junia V. (Autor)
Autor Corporativo: SpringerLink (Online service)
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Cham : Springer International Publishing : Imprint: Adis, 2014.
Edición:1st ed. 2014.
Temas:
Hematology.
Oncology.
Therapeutics.
Acceso en línea:Texto Completo

MARC

LEADER 00000nam a22000005i 4500
001 978-3-319-08350-6
003 DE-He213
005 20220119233929.0
007 cr nn 008mamaa
008 141106s2014 sz | s |||| 0|eng d
020 |a 9783319083506  |9 978-3-319-08350-6 
024 7 |a 10.1007/978-3-319-08350-6  |2 doi 
050 4 |a RC633-647 
072 7 |a MJF  |2 bicssc 
072 7 |a MED038000  |2 bisacsh 
072 7 |a MJF  |2 thema 
082 0 4 |a 616.15  |2 23 
100 1 |a Hughes, Timothy P.  |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
245 1 0 |a Handbook of Chronic Myeloid Leukemia  |h [electronic resource] /  |c by Timothy P Hughes, David M Ross, Junia V Melo. 
250 |a 1st ed. 2014. 
264 1 |a Cham :  |b Springer International Publishing :  |b Imprint: Adis,  |c 2014. 
300 |a XIII, 65 p. 14 illus., 12 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
505 0 |a Epidemiology and risk factors.- Pathophysiology.-Diagnosis -- Management of patients with CML -- Challenges of treatment: treatment-resistant CML -- Useful resources for your patients and caregivers. 
520 |a This concise, clinically focused pocket handbook assembles and synthesizes the latest developments and trends in the diagnosis and treatment of CML and provides an authoritative and convenient summary of the latest progress in TKI trials, the molecular monitoring of CML responses, and the development of new therapies to overcome resistance and improve patient care. Chronic myeloid leukemia (CML) is a rare type of leukemia (1-2 per 100,000 people) but is the most common chronic myeloproliferative neoplasm. CML remains a key model for the improved understanding of the pathophysiology of a malignancy at a molecular level; CML was the first cancer to be associated with a recurring chromosome abnormality, which generates the Philadelphia (Ph) chromosome and its associated fusion gene BCR-ABL1. The clinical outcome for patients with CML has changed dramatically in the past 15 years and this has been due to the development of tyrosine kinase inhibitors (TKIs), compounds that inhibit the activity of the oncogenic BCR-ABL1 protein. A number of first-, second- and third-generation TKIs are now available for the treatment of CML, although a number of treatment challenges remain, not least the development of treatment-resistant CML. Parallel to the development of specific drugs for treating CML, major advances have been made in the field of disease monitoring and standardization of response criteria. . 
650 0 |a Hematology. 
650 0 |a Oncology. 
650 0 |a Therapeutics. 
650 1 4 |a Hematology. 
650 2 4 |a Oncology. 
650 2 4 |a Therapeutics. 
700 1 |a Ross, David M.  |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
700 1 |a Melo, Junia V.  |e author.  |4 aut  |4 http://id.loc.gov/vocabulary/relators/aut 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer Nature eBook 
776 0 8 |i Printed edition:  |z 9783319083513 
776 0 8 |i Printed edition:  |z 9783319083490 
856 4 0 |u https://doi.uam.elogim.com/10.1007/978-3-319-08350-6  |z Texto Completo 
912 |a ZDB-2-SME 
912 |a ZDB-2-SXM 
950 |a Medicine (SpringerNature-11650) 
950 |a Medicine (R0) (SpringerNature-43714) 

Ejemplares similares